LAB

BOSTON (AP) — BOSTON (AP) — Standard BioTools Inc. (LAB) on Tuesday reported net income of $127.1 million in its first quarter. On a per-share basis, the Boston-based company said it had profit of 33 cents. Losses, adjusted for one-time gains and costs, were 2 cents per share. The company that makes equipment to control fluids posted revenue of $21.1 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LAB at https://www.zacks.com/ap/LAB

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: First quarter 2026 revenue of $21.1 million 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026 $524 million in cash & investments as of March 31, 2026, excluding $25 million earnout received after quarter end, to fuel inorganic growth strategy “We delivered a strong start to 2026, with first quarter performance coming in above expectations,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are operating our base business with consistency, delivering year-over-year top-line growth, and our cost savings initiatives are taking hold with a 78% improvement in adjusted EBITDA to a loss of $3.1 million in the quarter, reinforcing our path to profitability in 2026.” Dr. Egholm continued, “With the sale of SomaLogic to Illumina complete, we are fully focused on strategic capital deployment to transform the business. Our strong balance sheet, with approximately $550 million in cash and investments inclusive of a $25 million earnout received after quarter end, provides substantial flexibility to pursue attractive opportunities and create shareholder value.” First Quarter 2026 Financial Results: Continuing Operations Revenue was $21.1 million in the first quarter of 2026, up 5% year-over-year. Consumables revenue was $11.0 million in the first quarter of 2026, up 35% year-over-year. Greater consumables revenue in the quarter reflected growth across all product categories, primarily driven by microfluidics. Instruments revenue was $4.5 million in the first quarter of 2026, down 33% year-over-year. Instrument revenue in the quarter, compared against particularly strong prior year results, remained impacted by capital-constrained end-markets. Services revenue, which is predominantly Field Services, was $5.7 million in the first quarter of 2026, up 5% year-over-year. Gross margins in the first quarter of 2026 were approximately 53.5%, versus 54.6% in the first quarter of 2025; and non-GAAP gross margins in the first quarter of 2026 were approximately 57.7%, versus 57.1% in the first quarter of 2025. Gross margins and non-GAAP gross...

BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (NASDAQ: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™. Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/. Patent and License Information: standardbio.com/legal/notices. ©2026 Standard BioTools Inc. All rights reserved. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures. Investor Contact: [email protected]

TORONTO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representing 49.27% of the issued and outstanding Common Shares as of the record date for the Meeting (January 15, 2026), were represented at the Meeting. Shareholders overwhelmingly voted in line with the Corporation’s recommendations on the BLUE Form of Proxy and BLUE Voting Instruction Form for the following matters voted on at the Meeting: The Corporation’s director nominees were elected with an average of 97.39% votes cast ‘FOR’, as follows: The results of other items of business presented by the Corporation at the Meeting passed, as follows: The Dissident Resolutions did not pass at the Meeting, as follows: “I am grateful for the overwhelming support of our shareholders, many of whom I engaged with throughout this proxy contest.”, said Roger Moss President and CEO of LabGold. “It was very clear to me that our shareholders did not want to be associated with Coloured Ties, who they believed was just trying to get control of our treasury for self-serving purposes. Now that the shareholder vote is behind us, I look forward to sharing more exploration updates in the future while working to create value for all our shareholders.” The formal report on voting results with respect to all matters voted upon at the Meeting will be filed under the Corporation’s profile on SEDAR+ at www.sedarplus.ca. About Labrador Gold Corp. LabGold is a Canadian-based mineral exploration company focused on the acquisition and exploration of prospective gold projects in Eastern Canada. The recently announced Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, co...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Standard BioTools Inc. (LAB) on Tuesday reported earnings of $19.3 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had net income of 5 cents. Earnings, adjusted for one-time gains and costs, came to 6 cents per share. The company that makes equipment to control fluids posted revenue of $23.8 million in the period. For the year, the company reported a loss of $74.9 million, or 20 cents per share. Revenue was reported as $85.3 million. Standard BioTools expects full-year revenue in the range of $80 million to $85 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LAB at https://www.zacks.com/ap/LAB

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 million Fully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 2026 Approximately $550 million in cash & investments following the closing of the SomaLogic transaction on January 30, 20261 to fuel inorganic growth strategy “We delivered a strong finish to the year with better-than-expected performance, driven by disciplined execution across the business,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “Our team continued to deliver tangible efficiency gains, fully operationalizing over $40 million in previously announced cost savings and exiting the year with meaningfully lower run-rate operating expenses, reinforcing progress toward achieving our 2026 profitability targets.” Dr. Egholm continued, “Looking ahead, we enter 2026 with a focused and streamlined business, a proven team executing with the rigor of the Standard BioTools Business System (SBS), a strong balance sheet following the strategic sale of SomaLogic to Illumina, and approximately $1 billion in NOL carryforwards. Taken together, these differentiated assets provide significant flexibility to pursue disciplined M&A and drive long-term shareholder value.” 1 This approximate cash and investments balance is unaudited and may be adjusted as a result of, among other things, completion of financial closing procedures and internal reviews. This financial information does not represent a comprehensive statement of the Company’s current financial results. Fourth Quarter 2025 Financial Results: Continuing Operations Following the announced sale of SomaLogic, Inc. (“SomaLogic”) and other specified assets to Illumina, Inc. (“Illumina”) in June 2025, which transaction closed in January 2026, all financial results in this section reflect continuing operations only. Revenue was $23.8 million in the fourth quarter of 2025, down 4% year-over-year. Consumables revenue was $9.0 million in the fourth quarter of 2025, down 17% year-over-y...

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representing 49.27% of the issued and outstanding Common Shares as of the record date for the Meeting (January 15, 2026), were represented at the Meeting. Shareholders overwhelmingly voted in line with the Corporation’s recommendations on the BLUE Form of Proxy and BLUE Voting Instruction Form for the following matters voted on at the Meeting: The Corporation’s director nominees were elected with an average of 97.39% votes cast ‘FOR’, as follows: The results of other items of business presented by the Corporation at the Meeting passed, as follows: The Dissident Resolutions did not pass at the Meeting, as follows: “I am grateful for the overwhelming support of our shareholders, many of whom I engaged with throughout this proxy contest.”, said Roger Moss President and CEO of LabGold. “It was very clear to me that our shareholders did not want to be associated with Coloured Ties, who they believed was just trying to get control of our treasury for self-serving purposes. Now that the shareholder vote is behind us, I look forward to sharing more exploration updates in the future while working to create value for all our shareholders.” The formal report on voting results with respect to all matters voted upon at the Meeting will be filed under the Corporation’s profile on SEDAR+ at www.sedarplus.ca. About Labrador Gold Corp. LabGold is a Canadian-based mineral exploration company focused on the acquisition and exploration of prospective gold projects in Eastern Canada. The recently announced Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, co...

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™. Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices. ©2026 Standard BioTools Inc. All rights reserved. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures. Investor Contact: [email protected]

Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million. For the full year 2025, the Company expects combined company revenue of approximately $185 million and revenue from continued operations of approximately $85 million. "Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations,” said Michael Egholm, PhD, Chief Executive Officer of Standard BioTools. “Amid a shifting macro backdrop, the team remained focused – managing what we could control to drive the business forward.” Dr. Egholm added, “We continued our path toward profitability, taking targeted actions to streamline the organization and sharpen our operating model. Grounded in continuous improvement, we optimized workflows, improved our cost structure and drove rigor across the Company. These efforts strengthened our foundation and leave us exiting the year a leaner organization and a more resilient business.” “As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we expect to have approximately $550 million in cash and a base business on its way to positive adjusted EBITDA — a combination that creates real strategic flexibility. With an experienced team, a simplified footprint and substantial cash, we are well positioned to pursue disciplined M&A as we work to build a diversified leader in life sciences." Standard BioTools plans to report its fourth quarter and full year 2025 financial results later this quarter, at which time the Company will discuss its full 2025 financial results in more detail and provide its outlook for 2026. The Company’s unaudited, preliminary 2025 revenue results are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information doe...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 million Implemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to achieve positive adjusted EBITDA target in 2026 $217.0 million in cash & cash equivalents as of September 30, 2025; Approximately $550 million in cash & cash equivalents expected at close of transaction with Illumina in first half of 2026 to fuel inorganic growth strategy “The third quarter marked another period of solid execution as we sharpen our focus and position Standard BioTools for the next stage,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “Our commercial team delivered consistent overall performance amid a still-evolving macro environment, and with cost savings initiatives beginning to take hold, we are simplifying operations, increasing productivity and driving the go-forward business toward profitability expected in 2026. Combined with a strong balance sheet at quarter end and the significant cash injection expected from the pending Illumina transaction, we are well positioned to expand our portfolio through strategic M&A that we believe will fuel growth and deliver long-term value for our shareholders.” Operational Restructuring In September, as previously disclosed in the Company’s SEC filings, the Company implemented a phased operational restructuring plan expected to deliver over $40 million in total annualized cost savings, to be fully realized in 2026. The plan included an aggregate reduction-in-force of approximately 20% of its global workforce as well as initiatives designed to increase operating efficiency, reduce costs, and align resources with the Company’s long-term strategic objectives. These actions reinforce the Company’s path to generating positive adjusted EBITDA expected in 2026. “Given the current operating environment, these decisions were important to keep our organization lean, focused and positioned to emerge stronger tomorrow than we are today,” said Alex Kim, Chief Financial Officer of Standard BioTools. “I want to sincerely th...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Standard BioTools Inc. (LAB) on Tuesday reported a loss of $34.7 million in its third quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 9 cents. Losses, adjusted for restructuring costs and stock option expense, came to 4 cents per share. The company that makes equipment to control fluids posted revenue of $19.6 million in the period. Standard BioTools expects full-year revenue in the range of $165 million to $175 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LAB at https://www.zacks.com/ap/LAB

This article first appeared on GuruFocus. Standard BioTools Inc (NASDAQ:LAB) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $18.00 million, and the earnings are expected to come in at -$0.06 per share. The full year 2025's revenue is expected to be $86.36 million and the earnings are expected to be -$0.24 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 5 Warning Signs with LAB. Is LAB fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Standard BioTools Inc (NASDAQ:LAB) have declined from $169.15 million to $86.36 million for the full year 2025 and from $189.75 million to $79.73 million for 2026 over the past 90 days. Earnings estimates have improved, increasing from -$0.28 per share to -$0.24 per share for the full year 2025 and from -$0.17 per share to -$0.12 per share for 2026 over the past 90 days. In the previous quarter ending on June 30, 2025, Standard BioTools Inc's (NASDAQ:LAB) actual revenue was $21.76 million, which missed analysts' revenue expectations of $39.82 million by -45.35%. The company's actual earnings were -$0.09 per share, missing analysts' earnings expectations of -$0.08 per share by -12.50%. After releasing the results, Standard BioTools Inc (NASDAQ:LAB) was up by 2.34% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Standard BioTools Inc (NASDAQ:LAB) is $1.78, with a high estimate of $2.00 and a low estimate of $1.55. The average target implies an upside of 47.92% from the current price of $1.20. Based on GuruFocus estimates, the estimated GF Value for Standard BioTools Inc (NASDAQ:LAB) in one year is $0.40, suggesting a downside of -66.67% from the current price of $1.20. Based on the consensus recommendation from 3 brokerage firms, Standard BioTools Inc's (NASDAQ:LAB) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.